Verve Therapeutics Key Executives
This section highlights Verve Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Verve Therapeutics
( total contacts)
Verve Therapeutics Earnings
This section highlights Verve Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
$5.89
Stock Price
$523.01M
Market Cap
200.00K
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Verve Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $32.33M | $11.76M | $1.94M | $- | $- |
| Cost of Revenue | $- | $5.46M | $6.71M | $3.38M | $1.33M |
| Gross Profit | $32.33M | $6.30M | $-4.77M | $-3.38M | $-1.33M |
| Gross Profit Ratio | 100.00% | 53.60% | -245.75% | 0.00% | 0.00% |
| Research and Development Expenses | $204.35M | $184.95M | $130.09M | $68.20M | $35.37M |
| General and Administrative Expenses | $56.65M | $49.94M | $37.53M | $18.86M | $5.26M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $56.65M | $49.94M | $37.53M | $18.86M | $5.26M |
| Other Expenses | $- | $- | $1.49M | $-33.39M | $-5.24M |
| Operating Expenses | $260.99M | $234.88M | $167.63M | $87.07M | $40.63M |
| Cost and Expenses | $260.99M | $234.88M | $167.63M | $87.07M | $40.63M |
| Interest Income | $- | $- | $6.87M | $142.00K | $162.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $5.46M | $6.71M | $3.38M | $1.33M |
| EBITDA | $-228.66M | $-217.67M | $-162.88M | $-85.53M | $-39.30M |
| EBITDA Ratio | -707.23% | -1851.24% | -8391.71% | 0.00% | 0.00% |
| Operating Income | $-228.66M | $-223.12M | $-165.69M | $-87.07M | $-40.63M |
| Operating Income Ratio | -707.23% | -1897.64% | -8536.17% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $30.30M | $23.33M | $8.35M | $-33.25M | $-5.08M |
| Income Before Tax | $-198.36M | $-199.79M | $-157.33M | $-120.31M | $-45.70M |
| Income Before Tax Ratio | -613.51% | -1699.21% | -8105.82% | 0.00% | 0.00% |
| Income Tax Expense | $349.00K | $275.00K | $53.00K | $-1.68M | $-162.00K |
| Net Income | $-198.71M | $-200.07M | $-157.39M | $-118.64M | $-45.54M |
| Net Income Ratio | -614.59% | -1701.55% | -8108.55% | 0.00% | 0.00% |
| EPS | $-2.36 | $-3.12 | $-2.91 | $-2.45 | $-0.94 |
| EPS Diluted | $-2.35 | $-3.12 | $-2.91 | $-2.45 | $-0.94 |
| Weighted Average Shares Outstanding | 84.23M | 64.18M | 54.02M | 48.51M | 48.22M |
| Weighted Average Shares Outstanding Diluted | 84.63M | 64.18M | 54.02M | 48.51M | 48.22M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.08M | $6.87M | $6.69M | $5.70M | $5.14M | $3.12M | $2.09M | $1.40M | $1.01M | $929.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $1.75M | $1.67M | $1.63M | $1.52M | $3.20M | $3.03M | $2.76M | $2.55M | $2.00M | $1.15M | $1.01M | $969.00K | $1.76M | $357.00K | $294.00K | $- | $- | $- | $- |
| Gross Profit | $13.08M | $5.11M | $5.03M | $4.06M | $3.63M | $-82.00K | $-933.00K | $-1.35M | $-1.54M | $-1.07M | $-1.15M | $-1.01M | $-969.00K | $-1.76M | $-357.00K | $-294.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 100.00% | 74.50% | 75.10% | 71.30% | 70.50% | -2.60% | -44.60% | -96.50% | -152.30% | -115.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $55.05M | $49.94M | $50.98M | $48.38M | $46.81M | $43.77M | $47.26M | $47.11M | $37.28M | $35.20M | $33.12M | $24.49M | $25.94M | $17.50M | $13.42M | $11.35M | $15.58M | $7.62M | $5.65M | $6.52M |
| General and Administrative Expenses | $14.10M | $13.84M | $14.55M | $14.16M | $12.28M | $11.69M | $13.42M | $12.55M | $11.44M | $9.59M | $9.07M | $7.43M | $6.60M | $6.01M | $3.54M | $2.72M | $2.02M | $1.35M | $1.03M | $846.00K |
| Selling and Marketing Expenses | $- | $- | $-1.67M | $-1.63M | $-1.52M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $14.10M | $13.84M | $12.88M | $12.53M | $10.76M | $11.69M | $13.42M | $12.55M | $11.44M | $9.59M | $9.07M | $7.43M | $6.60M | $6.01M | $3.54M | $2.72M | $2.02M | $1.35M | $1.03M | $846.00K |
| Other Expenses | $- | $- | $1.67M | $78.00K | $-713.00K | $802.00K | $-662.00K | $738.00K | $2.18M | $-3.31M | $938.00K | $1.68M | $1.14M | $700.00K | $-36.01M | $778.00K | $-5.93M | $-55.00K | $-944.00K | $1.69M |
| Operating Expenses | $69.15M | $63.77M | $63.86M | $60.91M | $57.58M | $55.45M | $60.68M | $59.66M | $48.72M | $44.79M | $42.19M | $31.93M | $32.54M | $23.50M | $16.96M | $14.06M | $17.60M | $8.97M | $6.69M | $7.37M |
| Cost and Expenses | $69.15M | $63.77M | $65.53M | $62.54M | $59.09M | $55.45M | $60.68M | $59.66M | $48.72M | $44.79M | $42.19M | $31.93M | $32.54M | $23.50M | $16.96M | $14.06M | $17.60M | $8.97M | $6.69M | $7.37M |
| Interest Income | $- | $6.89M | $7.43M | $8.14M | $- | $5.84M | $5.44M | $5.55M | $- | $1.98M | $308.00K | $82.00K | $- | $53.00K | $5.00K | $20.00K | $- | $37.00K | $50.00K | $77.00K |
| Interest Expense | $- | $- | $- | $- | $6.28M | $- | $- | $- | $- | $1.98M | $308.00K | $82.00K | $- | $53.00K | $5.00K | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $1.70M | $1.75M | $1.67M | $1.63M | $1.52M | $3.20M | $3.03M | $2.76M | $2.55M | $2.00M | $1.15M | $1.01M | $969.00K | $1.76M | $357.00K | $294.00K | $253.00K | $624.00K | $286.00K | $165.00K |
| EBITDA | $-54.37M | $-55.16M | $-57.17M | $-55.21M | $-52.43M | $-50.86M | $-57.25M | $-57.13M | $-46.78M | $-43.14M | $-41.54M | $-31.41M | $-32.07M | $-23.09M | $-16.61M | $-13.77M | $-17.35M | $-8.35M | $-6.40M | $-7.20M |
| EBITDA Ratio | -415.65% | -803.44% | -854.33% | -969.48% | -1019.27% | -1678.99% | -2735.12% | -4149.50% | -4623.02% | -4721.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-56.07M | $-56.91M | $-58.84M | $-56.84M | $-53.95M | $-52.33M | $-58.58M | $-58.26M | $-47.71M | $-43.86M | $-42.19M | $-31.93M | $-32.54M | $-23.50M | $-16.96M | $-14.06M | $-17.60M | $-8.97M | $-6.69M | $-7.37M |
| Operating Income Ratio | -428.65% | -828.99% | -879.24% | -998.14% | -1048.76% | -1678.99% | -2799.00% | -4149.50% | -4714.43% | -4721.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $6.11M | $6.88M | $9.10M | $8.21M | $5.63M | $6.64M | $4.78M | $6.28M | $6.68M | $-1.33M | $1.25M | $1.76M | $1.20M | $753.00K | $-36.00M | $798.00K | $-5.93M | $-18.00K | $-894.00K | $1.77M |
| Income Before Tax | $-49.96M | $-50.03M | $-49.74M | $-48.63M | $-48.32M | $-45.69M | $-53.81M | $-51.98M | $-41.03M | $-45.19M | $-40.95M | $-30.17M | $-31.34M | $-22.75M | $-52.97M | $-13.26M | $-23.53M | $-8.99M | $-7.58M | $-5.60M |
| Income Before Tax Ratio | -381.97% | -728.75% | -743.26% | -853.91% | -939.35% | -1465.86% | -2570.81% | -3701.92% | -4054.55% | -4864.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $73.00K | $104.00K | $66.00K | $106.00K | $32.00K | $-67.00K | $176.00K | $-6.28M | $53.00K | $1.33M | $-1.25M | $-1.76M | $-1.20M | $-753.00K | $36.00M | $-798.00K | $5.93M | $18.00K | $894.00K | $-1.77M |
| Net Income | $-50.03M | $-50.13M | $-49.80M | $-48.74M | $-48.35M | $-45.76M | $-53.98M | $-45.69M | $-41.09M | $-46.52M | $-39.70M | $-28.41M | $-31.34M | $-22.75M | $-52.97M | $-13.26M | $-23.53M | $-8.99M | $-7.58M | $-5.60M |
| Net Income Ratio | -382.53% | -730.27% | -744.25% | -855.77% | -939.97% | -1468.01% | -2579.22% | -3254.34% | -4059.78% | -5007.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.58 | $-0.60 | $-0.59 | $-0.59 | $-0.69 | $-0.72 | $-0.87 | $-0.74 | $-0.67 | $-0.81 | $-0.82 | $-0.58 | $-0.65 | $-0.47 | $-1.10 | $-0.30 | $-0.81 | $-0.31 | $-0.26 | $-0.19 |
| EPS Diluted | $-0.58 | $-0.59 | $-0.59 | $-0.59 | $-0.69 | $-0.72 | $-0.87 | $-0.74 | $-0.67 | $-0.81 | $-0.82 | $-0.58 | $-0.65 | $-0.47 | $-1.10 | $-0.30 | $-0.81 | $-0.31 | $-0.26 | $-0.19 |
| Weighted Average Shares Outstanding | 86.87M | 84.23M | 84.23M | 83.13M | 69.67M | 63.21M | 61.95M | 61.79M | 61.46M | 57.21M | 48.67M | 48.57M | 48.03M | 47.99M | 47.95M | 43.82M | 29.17M | 29.17M | 29.17M | 29.17M |
| Weighted Average Shares Outstanding Diluted | 86.87M | 84.63M | 84.23M | 83.13M | 69.67M | 63.21M | 61.95M | 61.79M | 61.46M | 57.21M | 48.67M | 48.57M | 48.03M | 47.99M | 47.95M | 43.82M | 29.17M | 29.17M | 29.17M | 29.17M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $172.56M | $206.18M | $115.41M | $64.33M | $8.99M |
| Short Term Investments | $351.72M | $417.77M | $439.40M | $296.11M | $63.12M |
| Cash and Short Term Investments | $524.28M | $623.95M | $554.81M | $360.44M | $72.11M |
| Net Receivables | $3.25M | $5.90M | $1.01M | $- | $- |
| Inventory | $- | $- | $1 | $- | $- |
| Other Current Assets | $15.21M | $8.10M | $7.34M | $13.37M | $1.85M |
| Total Current Assets | $542.75M | $637.95M | $563.16M | $367.13M | $73.97M |
| Property Plant Equipment Net | $96.73M | $107.80M | $110.66M | $9.06M | $3.98M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $4.82M | $5.24M | $463.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.92M | $6.94M | $585.00K | $2.70M | $- |
| Total Non-Current Assets | $104.64M | $114.74M | $116.06M | $17.00M | $4.45M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $647.39M | $752.69M | $679.22M | $384.12M | $78.41M |
| Account Payables | $4.52M | $6.64M | $2.42M | $7.08M | $36.00K |
| Short Term Debt | $10.44M | $10.19M | $23.81M | $3.91M | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $3.60M | $- | $20.01M | $-12.99M | $90.00K |
| Other Current Liabilities | $24.34M | $20.18M | $8.86M | $11.04M | $7.19M |
| Total Current Liabilities | $42.91M | $37.01M | $35.09M | $22.02M | $7.32M |
| Long Term Debt | $59.54M | $64.72M | $70.01M | $- | $125.16M |
| Deferred Revenue Non-Current | $- | $48.56M | $20.01M | $- | $125.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $-125.28M |
| Other Non-Current Liabilities | $51.54M | $2.91M | $3.17M | $4.75M | $9.72M |
| Total Non-Current Liabilities | $111.08M | $116.18M | $93.20M | $4.75M | $135.01M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $153.99M | $153.19M | $128.29M | $26.77M | $142.32M |
| Preferred Stock | $- | $- | $- | $384.12M | $125.16M |
| Common Stock | $89.00K | $82.00K | $62.00K | $49.00K | $3.00K |
| Retained Earnings | $-743.01M | $-544.30M | $-344.24M | $-186.85M | $-66.54M |
| Accumulated Other Comprehensive Income Loss | $428.00K | $272.00K | $-694.00K | $-228.00K | $8.00K |
| Other Total Stockholders Equity | $1.24B | $1.14B | $895.80M | $544.38M | $2.62M |
| Total Stockholders Equity | $493.40M | $599.50M | $550.93M | $357.35M | $-63.91M |
| Total Equity | $493.40M | $599.50M | $550.93M | $357.35M | $-63.91M |
| Total Liabilities and Stockholders Equity | $647.39M | $752.69M | $679.22M | $384.12M | $78.41M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $647.39M | $752.69M | $679.22M | $384.12M | $78.41M |
| Total Investments | $351.72M | $417.77M | $439.40M | $296.11M | $63.12M |
| Total Debt | $69.98M | $74.91M | $81.92M | $1.96M | $125.16M |
| Net Debt | $-102.58M | $-131.27M | $-33.49M | $-62.38M | $116.17M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $172.56M | $158.71M | $141.49M | $144.20M | $206.18M | $78.37M | $70.04M | $508.69M | $115.41M | $550.71M | $72.89M | $91.42M | $64.33M | $148.13M | $387.45M | $99.40M | $8.99M | $-18.78M |
| Short Term Investments | $351.72M | $381.21M | $434.46M | $462.17M | $417.77M | $406.86M | $392.43M | $424.94M | $439.40M | $273.69M | $220.67M | $231.88M | $296.11M | $241.08M | $30.18M | $50.13M | $63.12M | $37.56M |
| Cash and Short Term Investments | $524.28M | $539.92M | $575.95M | $606.37M | $623.95M | $485.23M | $462.48M | $508.69M | $554.81M | $550.71M | $293.56M | $323.30M | $360.44M | $389.21M | $417.62M | $149.52M | $72.11M | $18.78M |
| Net Receivables | $3.25M | $2.63M | $3.04M | $5.77M | $5.90M | $3.15M | $2.09M | $1.40M | $1.01M | $929.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $1 | $- | $1 | $-9.10M | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $15.21M | $13.91M | $11.90M | $8.19M | $8.10M | $9.89M | $8.50M | $7.70M | $7.34M | $9.99M | $10.17M | $11.06M | $13.37M | $10.45M | $3.88M | $2.32M | $1.85M | $- |
| Total Current Assets | $542.75M | $556.46M | $590.89M | $620.33M | $637.95M | $498.26M | $473.07M | $508.69M | $563.16M | $561.63M | $298.64M | $328.83M | $367.13M | $394.44M | $419.56M | $151.84M | $73.97M | $18.78M |
| Property Plant Equipment Net | $96.73M | $99.55M | $101.93M | $104.55M | $107.80M | $107.84M | $110.02M | $111.06M | $110.66M | $106.49M | $13.19M | $12.47M | $9.06M | $8.91M | $6.42M | $5.20M | $3.98M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $4.77M | $4.77M | $4.77M | $4.77M | $4.82M | $4.82M | $4.82M | $4.82M | $5.24M | $5.24M | $5.24M | $5.24M | $463.00K | $463.00K | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.92M | $7.90M | $3.32M | $2.71M | $2.17M | $1.53M | $1.22M | $9.81M | $585.00K | $410.00K | $7.19M | $2.70M | $2.70M | $2.29M | $74.00K | $663.00K | $463.00K | $-18.78M |
| Total Non-Current Assets | $104.64M | $107.45M | $110.02M | $112.03M | $114.74M | $114.15M | $116.06M | $125.69M | $116.06M | $111.72M | $25.62M | $20.41M | $17.00M | $16.44M | $6.95M | $6.33M | $4.45M | $-18.78M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $647.39M | $663.91M | $700.91M | $732.36M | $752.69M | $612.41M | $589.13M | $634.38M | $679.22M | $673.36M | $324.27M | $349.24M | $384.12M | $410.88M | $426.52M | $158.17M | $78.41M | $- |
| Account Payables | $4.52M | $4.64M | $6.83M | $3.05M | $6.64M | $1.05M | $3.15M | $3.37M | $2.42M | $465.00K | $6.32M | $2.44M | $7.08M | $3.58M | $1.53M | $2.49M | $36.00K | $- |
| Short Term Debt | $10.44M | $20.74M | $20.59M | $10.22M | $20.38M | $20.24M | $20.09M | $22.37M | $23.81M | $17.81M | $1.81M | $2.86M | $1.96M | $4.59M | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $3.60M | $5.72M | $3.48M | $1.47M | $48.56M | $48.55M | $20.01M | $20.01M | $20.01M | $20.01M | $- | $- | $-12.99M | $8.13M | $152.00K | $136.00K | $- | $- |
| Other Current Liabilities | $24.34M | $11.55M | $9.47M | $16.55M | $9.99M | $13.29M | $9.79M | $7.81M | $8.86M | $10.74M | $17.71M | $9.50M | $12.99M | $12.08M | $7.12M | $4.06M | $7.28M | $- |
| Total Current Liabilities | $42.91M | $42.64M | $40.37M | $31.29M | $37.01M | $34.58M | $33.03M | $33.55M | $35.09M | $29.02M | $25.85M | $14.80M | $22.02M | $20.25M | $8.65M | $6.68M | $7.32M | $- |
| Long Term Debt | $59.54M | $60.89M | $62.18M | $63.45M | $64.72M | $66.69M | $67.82M | $68.93M | $70.01M | $71.01M | $- | $- | $- | $181.00K | $- | $218.92M | $- | $- |
| Deferred Revenue Non-Current | $50.27M | $50.73M | $51.15M | $51.73M | $48.56M | $48.55M | $20.01M | $20.01M | $20.01M | $20.01M | $- | $- | $- | $- | $13.00K | $53.00K | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-218.97M | $- | $- |
| Other Non-Current Liabilities | $1.28M | $1.09M | $1.11M | $2.81M | $2.91M | $2.22M | $3.04M | $2.41M | $3.17M | $5.37M | $2.09M | $3.05M | $4.75M | $5.51M | $12.47M | $8.94M | $135.01M | $- |
| Total Non-Current Liabilities | $111.08M | $112.71M | $114.45M | $117.99M | $116.18M | $117.46M | $90.88M | $91.35M | $93.20M | $96.39M | $2.09M | $3.05M | $4.75M | $5.69M | $12.47M | $227.92M | $135.01M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $153.99M | $155.35M | $154.82M | $149.29M | $153.19M | $152.04M | $123.91M | $124.90M | $128.29M | $125.41M | $27.93M | $17.85M | $26.77M | $25.94M | $21.12M | $234.60M | $142.32M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $410.88M | $426.52M | $218.92M | $125.16M | $25.48M |
| Common Stock | $89.00K | $85.00K | $85.00K | $84.00K | $82.00K | $64.00K | $62.00K | $62.00K | $62.00K | $61.00K | $49.00K | $49.00K | $49.00K | $48.00K | $48.00K | $3.00K | $3.00K | $- |
| Retained Earnings | $-743.01M | $-692.98M | $-642.85M | $-593.04M | $-544.30M | $-495.95M | $-450.19M | $-396.21M | $-344.24M | $-303.15M | $-257.96M | $-217.02M | $-186.85M | $-155.51M | $-132.76M | $-79.80M | $-66.54M | $- |
| Accumulated Other Comprehensive Income Loss | $428.00K | $1.14M | $-615.00K | $-500.00K | $272.00K | $-597.00K | $-754.00K | $-237.00K | $-694.00K | $-920.00K | $-938.00K | $-732.00K | $-228.00K | $-2.00K | $3.00K | $7.00K | $8.00K | $-19.55M |
| Other Total Stockholders Equity | $1.24B | $1.20B | $1.19B | $1.18B | $1.14B | $956.86M | $916.11M | $905.86M | $895.80M | $851.95M | $555.18M | $549.09M | $544.38M | $540.40M | $538.11M | $3.36M | $2.62M | $- |
| Total Stockholders Equity | $493.40M | $508.55M | $546.09M | $583.07M | $599.50M | $460.37M | $465.22M | $509.48M | $550.93M | $547.94M | $296.33M | $331.39M | $357.35M | $384.94M | $405.40M | $-76.43M | $-63.91M | $5.93M |
| Total Equity | $493.40M | $508.55M | $546.09M | $583.07M | $599.50M | $460.37M | $465.22M | $509.48M | $550.93M | $547.94M | $296.33M | $331.39M | $357.35M | $384.94M | $405.40M | $-76.43M | $-63.91M | $5.93M |
| Total Liabilities and Stockholders Equity | $647.39M | $663.91M | $700.91M | $732.36M | $752.69M | $612.41M | $589.13M | $634.38M | $679.22M | $673.36M | $324.27M | $349.24M | $384.12M | $410.88M | $426.52M | $158.17M | $78.41M | $5.93M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $647.39M | $663.91M | $700.91M | $732.36M | $752.69M | $612.41M | $589.13M | $634.38M | $679.22M | $673.36M | $324.27M | $349.24M | $384.12M | $410.88M | $426.52M | $158.17M | $78.41M | $5.93M |
| Total Investments | $351.72M | $381.21M | $439.23M | $466.94M | $422.54M | $406.86M | $392.43M | $424.94M | $439.40M | $273.69M | $220.67M | $231.88M | $296.11M | $241.08M | $30.18M | $50.13M | $63.12M | $37.56M |
| Total Debt | $69.98M | $71.25M | $72.48M | $73.67M | $74.91M | $76.81M | $77.86M | $80.11M | $81.92M | $79.92M | $907.00K | $1.43M | $1.96M | $2.48M | $- | $218.92M | $- | $- |
| Net Debt | $-102.58M | $-87.45M | $-69.01M | $-70.53M | $-131.27M | $-1.56M | $7.82M | $-428.58M | $-33.49M | $-470.80M | $-71.98M | $-89.99M | $-62.38M | $-145.66M | $-387.45M | $119.52M | $-8.99M | $18.78M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-198.71M | $-200.07M | $-157.39M | $-120.31M | $-45.70M |
| Depreciation and Amortization | $- | $5.46M | $2.80M | $1.53M | $1.33M |
| Deferred Income Tax | $- | $- | $- | $1.51M | $380.00K |
| Stock Based Compensation | $43.26M | $35.12M | $22.48M | $7.07M | $850.00K |
| Change in Working Capital | $-2.26M | $17.70M | $8.38M | $-2.91M | $2.64M |
| Accounts Receivables | $2.64M | $- | $-1.01M | $- | $- |
| Inventory | $- | $- | $1.01M | $- | $- |
| Accounts Payables | $-1.83M | $3.91M | $-5.22M | $6.83M | $-1.90M |
| Other Working Capital | $-3.07M | $13.79M | $13.60M | $-9.74M | $4.54M |
| Other Non Cash Items | $23.00K | $-7.75M | $1.39M | $35.23M | $5.24M |
| Net Cash Provided by Operating Activities | $-157.69M | $-149.55M | $-122.33M | $-77.88M | $-35.27M |
| Investments in Property Plant and Equipment | $- | $-9.28M | $-13.23M | $-4.36M | $-3.42M |
| Acquisitions Net | $- | $- | $142.72M | $234.74M | $47.70M |
| Purchases of Investments | $- | $-517.14M | $-479.40M | $-371.49M | $-98.48M |
| Sales Maturities of Investments | $- | $554.11M | $336.68M | $136.75M | $50.78M |
| Other Investing Activities | $74.88M | $- | $-142.72M | $-234.74M | $-47.70M |
| Net Cash Used for Investing Activities | $74.88M | $27.69M | $-155.96M | $-239.10M | $-51.13M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $46.73M | $210.46M | $326.50M | $285.21M | $92.63M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.46M | $2.12M | $2.46M | $91.88M | $92.63M |
| Net Cash Used Provided by Financing Activities | $49.20M | $212.58M | $328.96M | $377.09M | $92.63M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-33.62M | $90.72M | $50.67M | $60.11M | $6.24M |
| Cash at End of Period | $177.33M | $210.95M | $120.24M | $69.57M | $9.46M |
| Cash at Beginning of Period | $210.95M | $120.24M | $69.57M | $9.46M | $3.22M |
| Operating Cash Flow | $-157.69M | $-149.55M | $-122.33M | $-77.88M | $-35.27M |
| Capital Expenditure | $-3.74M | $-9.28M | $-13.23M | $-4.36M | $-3.42M |
| Free Cash Flow | $-161.43M | $-158.83M | $-135.56M | $-82.24M | $-38.69M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-50.03M | $-50.13M | $-49.80M | $-48.74M | $-48.35M | $-45.76M | $-53.98M | $-51.98M | $-41.09M | $-45.19M | $-40.95M | $-30.17M | $-31.34M | $-22.75M | $-52.97M | $-13.26M | $-23.53M | $-8.99M | $-7.58M | $-5.60M |
| Depreciation and Amortization | $1.70M | $1.75M | $1.67M | $1.63M | $1.52M | $1.47M | $1.34M | $1.13M | $925.00K | $717.00K | $648.00K | $514.00K | $472.00K | $412.00K | $357.00K | $294.00K | $253.00K | $624.00K | $286.00K | $165.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-10.56M | $-3.49M | $-3.70M | $- | $- | $- | $- | $- | $740.00K | $412.00K | $148.00K | $208.00K | $179.00K | $135.00K | $60.00K | $6.00K |
| Stock Based Compensation | $10.45M | $10.82M | $11.65M | $10.34M | $9.25M | $8.82M | $9.01M | $8.02M | $6.70M | $5.92M | $5.65M | $4.20M | $2.76M | $2.29M | $1.35M | $670.00K | $442.00K | $213.00K | $100.00K | $95.00K |
| Change in Working Capital | $-2.85M | $-1.12M | $5.75M | $-4.04M | $-2.22M | $26.22M | $-2.98M | $-3.31M | $3.25M | $4.91M | $7.83M | $-7.61M | $-34.00K | $-2.37M | $1.76M | $-2.27M | $1.75M | $1.64M | $-954.00K | $204.00K |
| Accounts Receivables | $-626.00K | $410.00K | $2.69M | $168.00K | $-2.77M | $- | $- | $1.40M | $-83.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $83.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $491.00K | $-2.57M | $3.55M | $-3.31M | $4.50M | $-2.06M | $-14.00K | $1.49M | $1.20M | $-5.39M | $4.09M | $-5.11M | $3.48M | $2.06M | $-645.00K | $1.93M | $-2.20M | $1.34M | $-940.00K | $-104.00K |
| Other Working Capital | $-2.71M | $1.04M | $-488.00K | $-904.00K | $-3.94M | $28.28M | $-2.97M | $-1.49M | $2.06M | $10.30M | $3.74M | $-2.50M | $-3.52M | $-4.43M | $2.41M | $-4.20M | $3.95M | $295.00K | $-14.00K | $308.00K |
| Other Non Cash Items | $-111.00K | $-924.00K | $5.32M | $14.47M | $9.69M | $923.00K | $2.35M | $-2.96M | $-2.69M | $4.47M | $63.00K | $-448.00K | $-642.00K | $645.00K | $36.01M | $-778.00K | $5.93M | $55.00K | $944.00K | $-1.69M |
| Net Cash Provided by Operating Activities | $-40.84M | $-39.61M | $-34.16M | $-43.08M | $-40.68M | $-11.81M | $-47.96M | $-49.10M | $-32.89M | $-29.18M | $-26.76M | $-33.51M | $-28.04M | $-21.36M | $-13.34M | $-15.14M | $-14.97M | $-6.32M | $-7.14M | $-6.82M |
| Investments in Property Plant and Equipment | $-1.39M | $-936.00K | $-980.00K | $-433.00K | $-2.19M | $-1.06M | $-2.66M | $-3.38M | $-4.97M | $-2.64M | $-2.72M | $-2.91M | $-981.00K | $-1.00M | $-1.31M | $-1.07M | $-953.00K | $-1.02M | $-396.00K | $-1.05M |
| Acquisitions Net | $- | $- | $- | $- | $6.71M | $10.77M | $-35.69M | $-18.77M | $163.34M | $52.88M | $-10.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-73.07M | $-74.83M | $-111.91M | $-164.19M | $-122.32M | $-147.94M | $-113.12M | $-133.75M | $-257.32M | $-147.83M | $-74.25M | $- | $-137.00M | $-223.31M | $- | $-11.18M | $-10.16M | $-15.20M | $-73.13M | $- |
| Sales Maturities of Investments | $104.00M | $132.58M | $143.04M | $122.99M | $115.61M | $137.17M | $148.81M | $152.52M | $93.98M | $94.95M | $84.75M | $63.00M | $81.00M | $12.00M | $19.80M | $23.96M | $23.00M | $13.50M | $4.59M | $9.69M |
| Other Investing Activities | $- | $- | $31.13M | $-41.20M | $-6.71M | $-10.77M | $35.69M | $18.77M | $-163.34M | $-52.88M | $10.50M | $63.00M | $-56.00M | $-211.31M | $19.80M | $12.78M | $12.84M | $-1.70M | $-68.54M | $9.69M |
| Net Cash Used for Investing Activities | $29.55M | $56.81M | $30.15M | $-41.63M | $-8.89M | $-11.83M | $33.02M | $15.39M | $-168.31M | $-55.52M | $7.78M | $60.09M | $-56.98M | $-212.32M | $18.49M | $11.71M | $11.89M | $-2.72M | $-68.94M | $8.64M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $24.30M | $-1.60M | $-51.00K | $22.48M | $176.76M | $31.71M | $-65.00K | $1.99M | $38.59M | $287.90M | $445.00K | $505.00K | $93.76M | $-867.00K | $282.90M | $93.83M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $472.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $849.00K | $14.00K | $1.30M | $250.00K | $624.00K | $213.00K | $1.23M | $51.00K | $1.01M | $503.00K | $445.00K | $505.00K | $1.22M | $-867.00K | $282.90M | $93.83M | $8.00K | $- | $62.89M | $29.73M |
| Net Cash Used Provided by Financing Activities | $25.15M | $14.00K | $1.30M | $22.73M | $177.38M | $31.92M | $1.23M | $2.04M | $39.60M | $288.41M | $445.00K | $505.00K | $1.22M | $-867.00K | $282.90M | $93.83M | $8.00K | $- | $62.89M | $29.73M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-15.09M | $-3.18M | $18.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $13.85M | $21.99M | $-2.71M | $-61.98M | $127.81M | $8.28M | $-13.70M | $-31.67M | $-161.61M | $203.72M | $-18.53M | $27.09M | $-83.80M | $-234.54M | $288.05M | $90.40M | $-3.08M | $-9.04M | $-13.19M | $31.55M |
| Cash at End of Period | $177.33M | $163.48M | $141.49M | $144.20M | $206.18M | $83.14M | $74.87M | $88.57M | $120.24M | $281.84M | $78.13M | $96.66M | $69.57M | $153.37M | $387.91M | $99.86M | $9.46M | $12.54M | $21.58M | $34.77M |
| Cash at Beginning of Period | $163.48M | $141.49M | $144.20M | $206.18M | $78.37M | $74.87M | $88.57M | $120.24M | $281.84M | $78.13M | $96.66M | $69.57M | $153.37M | $387.91M | $99.86M | $9.46M | $12.54M | $21.58M | $34.77M | $3.22M |
| Operating Cash Flow | $-40.84M | $-39.61M | $-34.16M | $-43.08M | $-40.68M | $-11.81M | $-47.96M | $-49.10M | $-32.89M | $-29.18M | $-26.76M | $-33.51M | $-28.04M | $-21.36M | $-13.34M | $-15.14M | $-14.97M | $-6.32M | $-7.14M | $-6.82M |
| Capital Expenditure | $-1.39M | $-936.00K | $-980.00K | $-433.00K | $-2.19M | $-1.06M | $-2.66M | $-3.38M | $-4.97M | $-2.64M | $-2.72M | $-2.91M | $-981.00K | $-1.00M | $-1.31M | $-1.07M | $-953.00K | $-1.02M | $-396.00K | $-1.05M |
| Free Cash Flow | $-42.23M | $-40.54M | $-35.14M | $-43.52M | $-42.87M | $-12.87M | $-50.62M | $-52.47M | $-37.86M | $-31.81M | $-29.48M | $-36.41M | $-29.02M | $-22.36M | $-14.65M | $-16.21M | $-15.93M | $-7.35M | $-7.54M | $-7.88M |
Verve Therapeutics Dividends
Explore Verve Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Verve Therapeutics News
Read the latest news about Verve Therapeutics, including recent articles, headlines, and updates.
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/verve-therapeutics-inc-lawsuit-submission-form?prid=109744&wire=1 or contact Joseph E. Levi, Esq.
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/verve-therapeutics-inc-lawsuit-submission-form?prid=109723&wire=1 or contact Joseph E. Levi, Esq.
Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV
LOS ANGELES , Oct. 28, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm
LOS ANGELES , Oct. 28, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ: VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Lost Money on Verve Therapeutics, Inc. (VERV)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/verve-therapeutics-inc-lawsuit-submission-form?prid=109623&wire=1 or contact Joseph E. Levi, Esq.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for VERV.